Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 448 across all filing types
Latest filing 2024-11-11 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Monitoring Agency Report
Regulatory Filings
2024-11-11 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings
2024-11-11 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is dated November 11, 2024, and is addressed to stock exchanges referencing SEBI regulations related to disclosure requirements. It is titled 'Investors Presentation- Quarter II and Half year ended on September 30, 2024 of F.Y. 2024-25 – Orchid Pharma Limited.' The content includes detailed financial performance data for Q2 and half-year 2024-25, including sales, EBITDA, PBT, PAT, and various financial ratios and charts. The document explicitly states it is an 'Investors Presentation' and includes comprehensive financial highlights and analysis. There is no indication that this is a full annual report, audit report, or earnings release summary; rather, it is a detailed presentation aimed at investors covering quarterly and half-year financials. Therefore, the document fits the category of an Investor Presentation (IP). The document length (6454 characters) and detailed financial data support this classification with high confidence.
2024-11-11 English
Financial Result Updates
Regulatory Filings
2024-11-11 English
Outcome of Board Meeting
Regulatory Filings
2024-11-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation about the schedule of an Analysts/Investors Earnings Call for the quarter and half year ended September 30, 2024. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations and SEBI Circulars, indicating a regulatory announcement. The content includes details about the timing, participants, and dial-in numbers for the earnings call, but does not contain any financial results or substantive financial data itself. The document is short (3891 characters) and serves as a notice or invitation to the earnings call rather than the call transcript or financial report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement about the earnings call schedule, not the earnings release or transcript itself.
2024-11-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.